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HER2-positive breast cancers (HER2+ BC) are an aggressive subset characterized 
by therapeutic resistance in ~40-60% of patients. We hypothesized that modulating energy-
responsive pathways through either dietary restriction or pharmacological metabolic 
reprogramming interventions (MRI) would increase the efficacy of HER2-directed therapies 
trastuzumab and lapatinib. Dietary restriction was modeled in vitro and the efficacy of 
lapatinib was increased under serum-restricted conditions. This effect was recapitulated with 
MRIs and we determined that inhibition of IGF1R/insulin receptor and mTORC1 increased 
the antiproliferative effects of lapatinib. Ongoing work is investigating the impact of 
intermittent fasting regimens on therapeutic efficacy in vivo by restricting the dietary intake of 
mice with HER2+ BC for 48 hours coinciding with the administration of trastuzumab or 
lapatinib. We conclude that inhibition of metabolic pathways implicated in HER2+ BC drug 
resistance through intermittent fasting regimens and pharmacological MRIs has the potential 
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CHAPTER 1: INTRODUCTION 
 
HER2-Positive Breast Cancer Overview 
In the United States, breast cancer (BC) is the second leading cause of cancer 
death among women, with an estimated 252,000 new invasive breast cancer cases 
diagnosed annually (1). Human epidermal growth factor receptor (HER2)-positive  
breast cancers are defined by overexpression of the HER2 protein or amplification of 
the HER2 gene copy number (1). This molecular subtype accounts for 15-20% of early 
breast cancers and 35% of locally advanced and metastatic breast cancers (2). 
Compared to HER2-negative breast cancers, at time of diagnosis HER2-positive 
breast cancers are typically larger in size, more likely to be node-positive, and 
classified as a higher grade (3). Importantly, the growth and proliferation of these 
tumor cells is primarily driven by HER2, a phenomenon termed oncogene addiction. 
For this reason, the advent of HER2-directed therapeutics, including antibodies, 
antibody-drug conjugates, and tyrosine kinase inhibitors has demonstrated long-term 
clinical benefits and improved patient outcomes. However, new strategies to combat 
relapse, metastasis, and intrinsic and acquired resistance to therapies are required (4).  
Signaling Mechanisms 
The gene encoding HER2 (ERBB2) is a member of the ErbB receptor tyrosine 
kinase family. Homo- or heterodimerization of HER2 with one of multiple ligand-bound 
epidermal growth factor receptors (HER1, HER3, HER4) results in phosphorylation of 
the intracellular domains of the receptor tyrosine kinases (RTK) and recruitment of 
molecules to initiate several signaling cascades (5). The most common HER2 signaling 




kinase (PI3K/AKT) and mitogen-activated protein kinase (MAPK) cascades (6) (see 
Figure 1). In the MAPK cascade, adaptor proteins bind phosphorylated HER2 and 
activate RAS, a protein kinase, that initiates a cascade to activate extracellular signals-
regulated kinases 1 and 2 (ERK1/2). ERK interacts with kinases and transcription 
factors to promote cell growth, proliferation, and survival (7). The PI3K/AKT pathway is 
activated by HER2/RTK dimerization and intracellular phosphorylation. The 
heterodimer PI3K is recruited and activated to phosphorylate plasma membrane 
intrinsic protein (PIP2) to PIP3. PIP3 induces translocation of AKT to the plasma 
membrane where it regulates proteins involved in cell survival. Through these 
interactions, the PI3K/AKT activation is involved with inhibition of apoptosis and 
activation of survival pathways (8). These pathways can be inappropriately activated in 
cells that overexpress HER2 via HER2-induced changes in HER1 autophosphorylation 
of specific tyrosine residues, resulting in stabilized signaling through HER1 (9). This 
change in tyrosine phosphorylation patterns bypasses regulatory mechanisms, 







Figure 1. HER2 breast cancer signaling mechanisms 
 
Therapeutic Strategies  
The aberrant growth signals promoted by HER2 dimerization are effectively 
blocked with a regimen of HER2-directed therapies used in combination with 
chemotherapy.  In HER2-positive early breast cancer, the standard of care is a 
combination of neoadjuvant chemotherapy, breast surgery, and 12 months of 




domain of HER2 that blocks signaling independent of ligand activity (10-12). For the 
treatment of metastatic HER2-positive breast cancer, trastuzumab combined with 
paclitaxel or docetaxel is the standard first-line treatment (13). In advanced stages of 
this disease, lapatinib, a small-molecule tyrosine kinase inhibitor, is inducated (14, 
15).  
Lapatinib is a reversible inhibitor of HER1 and HER2 tyrosine kinases which 
prevents autophosphorylation by blocking the cytoplasmic ATP-binding domain (16). 
In clinical trials, weekly paclitaxel chemotherapy with trastuzumab alone, lapatinib 
alone, or trastuzumab combined with lapatinib significantly increased the rate of 
pathologic complete response (pCR) compared to trastuzumab alone (46.8% in 
combination and 27.6% in trastuzumab alone); however, in other clinical trials, there 
were no significant differences pCR when trastuzumab was combined with lapatinib 
following treatment with doxorubicin, cyclophosphamide and paclitaxel (12). Other 
tyrosine kinase inhibitors being explored for the treatment of HER2-positive breast 
cancer, including afatinib and neratinib, irreversible inhibitors of HER1/2/4 have yet 
to be proven more effective in combination with trastuzumab than the existing 
standard of care (12). 
In contrast, there are several proposed mechanisms for the actions of 
trastuzumab including HER2 internalization and degradation, induction of antibody-
dependent cellular cytotoxicity (ADCC), and interference with the MAPK and 
PI3K/AKT signaling cascades (17). More recently, the addition of pertuzumab, a 
humanized monoclonal antibody that works complementary with trastuzumab by 
blocking HER2/HER3 dimerization with HER family receptors, has been approved 




and docetaxel (18).  Contributing to the arsenal of anti-HER2 therapies, trastuzumab 
emtansine (T-DM1) has also been approved. T-DM1 is a conjugate of trastuzumab 
and the cytotoxic agent DM1, which inhibits microtubule polymerization. T-DM1 is 
currently approved for metastatic HER2-positive breast cancer. Unlike the 
combination of trastuzumab and standard chemotherapy, T-DM1 reduces systemic 
cytotoxic exposure by directing its effects to HER2-overexpressing cells alone; 
however, the combination of T-DM1 plus pertuzumab has not demonstrated clinically 
meaningful improvement in progression-free survival compared to trastuzumab plus 











Drug Resistance  
The clinical improvements that have been achieved since the introduction of 
HER2-directed therapies is especially remarkable in the metastatic setting where 
overall survival has been extended to 4.5 years with the use of trastuzumab, 
pertuzumab, and chemotherapy compared to chemotherapy alone (20). However, the 
development of new therapeutic strategies is imperative because approximately 40 to 
60 percent of patients exhibit intrinsic resistance or develop secondary resistance to 




trastuzumab (21). The proposed mechanisms that cancer cells use to evade 
trastuzumab-induced cell death include impaired binding of the antibody due to 
mutations in the HER2 kinase domain, failure to trigger immune-mediated destruction, 
upregulation of HER2 downstream signaling pathways, and signaling through alternate 
pathways via activation of insulin-like growth factor 1 receptor (IGF1R), tyrosine-
protein kinase Met (cMET), and HER1 (22, 23). Additional mechanisms of 
trastuzumab-specific resistance that have been proposed include HER2 proteolysis, 
Mucin-4 overexpression, and loss of phosphatidylinositol 3,4,5-trisphosphate 3-
phosphatase (PTEN) (24). Recent work has identified that high expression and 
activation of specific RTKs, including IGF1R, TYRO3, and PDGFR-beta, are involved 
in anti-HER2 drug resistance, as signaling through these receptors maintains 
activation of pro-growth pathways and suppress cellular senescence (25). HER2-
overexpressing cells also use other RTKs to evade cell death upon treatment with 
lapatinib. Similar to mechanisms of trastuzumab resistance, some cancer cells are 
able to reactivate the PIK3/AKT and mammalian target of rapamycin (mTOR) signaling 
axes by overexpressing the tyrosine-protein kinase receptor UFO (26). Alterations in 
receptor tyrosine kinase activities in response to treatment with HER2-directed therapy 
modulates distinct metabolic effects that allow cancer cells to evade growth inhibition 
and cell death. In models of drug resistance for trastuzumab and lapatinib, alterations 
in glucose and glutamine utilization have been observed. For example, in HER2-
overexpressing cells, treatment with lapatinib modulates phosphorylation of a residue 
on fructose-2,6-biphosphatase 2 (PFKFB2), an important mediator of glycolysis that 
reduces glucose flux (27). However, in lapatinib-resistant cells, this phosphorylation 
event is diminished, allowing for maintenance of flux through glycolysis and increased 
expression of proteins in the glucose-deprivation network (27). Glucose and glutamine 
utilization are also impacted by reactivation of mTOR signaling via AXL (UFO) 




mTOR restores expression of steroid hormone receptor ERR1, a nuclear receptor that 
acts as a master regulator of cellular metabolism. While lapatinib-sensitive cells have 
decreased flux in glucose and glutamine utilization, re-activation of ERR1 in resistant 
cells mediates transcriptional reprogramming changes to re-establish glutamine 
metabolism in the presence of the drug (28). These mechanisms of drug resistance 
establish an important association between cellular energetics and response to anti-
HER2 therapies. Together, these studies argue for approaches which induce broad 
changes in cellular metabolic pathways in HER2-positive breast cancer cells, targeting 
flux through glucose and glutamine metabolism through regimens of dietary restriction 
or pharmacologic interventions that reprogram specific metabolic pathways.  
Project Goals 
 The goals of the project are as follows: 1) Characterize the phenotypic and 
mechanistic impact of nutrient restriction on HER2-amplified breast cancer cells.  2) 
Determine the impact of short-term fasting regimens on tumor progression and response to 
HER2-targeting therapies in vivo. 3) Identify pharmacologic interventions that target 
pathways associated with nutrient stress to attenuate growth and increase therapeutic 




CHAPTER 2: NUTRIENT STRESS ALTERS CELL GROWTH AND PROLIFERATION OF 
HER2-POSITIVE BREAST CANCER CELLS IN VITRO 
Background 
The Hursting lab has identified an association between dietary energy balance 
and breast cancer progression across multiple BC subtypes (29). Through preclinical 
studies on MMTV-HER2/neu transgenic mice, which hyperactively express the HER2 
oncogene, the impact of dietary energy balance on HER2-amplified breast cancer has 
been examined. Chronic caloric restriction (CR) was modeled by placing female MMTV-
HER2/neu transgenic and wild type FVB mice on either a low-fat control regimen (10 
kcal% fat), a 30% CR regimen relative to control, or a high-fat diet induced obesity (DIO, 
60 kcal% fat) regimen (30). Compared to the control and DIO groups, calorie restricted 
mice had decreased adiposity and obesity-related serum markers including IGF1, 
insulin, leptin, as well as preserved ER-alpha and ER-beta expression, increased 
disease-free survival rates, and reduced tumor burden (30). These novel findings 
highlight the need for further investigation of the mechanisms underlying these diet-
gene interactions in order develop strategies to exploit its metabolic targets without 
prolonged dietary restriction.  
Relative to untransformed cells, cancer cells have increased reliance on 
utilization of glucose for proliferative activities and growth factor signaling in serum for 
mitogenic activities. We developed an in vitro model to test whether breast cancer cells 
would show reduced cellular viability under low glucose and serum conditions, to test 
the hypothesis that this dependence may underlie the in vivo sensitivity of breast cancer 






Cell Lines Used 
Murine E18-9A-42 cells that were isolated from a spontaneous mammary tumor 
generated in transgenic FVB/N-Tg(MMTVneu)202Mul/J mice, referred to as MMTV/neu 
breast cancer cells, were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
containing 4.5g/L glucose supplemented with 10% bovine calf serum (BCS) and 1% 
penicillin/streptomycin. The human breast cancer cell lines SKBR3 (ATCC HTB-30) and BT-
474 (ATCC HTB-20) derived from breast adenocarcinoma and ductal carcinoma, 
respectively, were cultured in RPMI 1640 (phenol free) supplemented with 10% fetal bovine 
serum (FBS), glucose (4.5g/L), HEPES buffer (10mM), sodium pyruvate (1mM), and 1% 
penicillin/streptomycin.  Cells were maintained at 37C in a 5% humidified chamber. Nutrient 
stress conditions were modeled in vitro through manipulation of media glucose and serum 
concentrations as indicated. 
Nutrient Stress Conditions in vitro  
Murine E18-9A-42 cells that were isolated from a spontaneous mammary tumor 
generated in transgenic FVB/N-Tg(MMTVneu)202Mul/J mice, referred to as MMTV/neu 
breast cancer cells, were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
containing 4.5g/L glucose supplemented with 10% bovine calf serum (BCS) and 1% 
penicillin/streptomycin. To initially investigate the impact of nutrient stress in vitro we 
cultured cells in severe glucose- and serum-restricted conditions that are beyond 
physiologic parameters. Cells were treated with medias containing reduced serum (1% 
BCS), reduced glucose (1mM Glc), or reduced serum and reduced glucose (1% BCS/1mM 
Glc) compared to control media (10% BCS/25mM Glc) (31). Following these initial 
experiments, nutrient stressed conditions were expanded to include more physiologically 
relevant conditions in vitro.  MMTV/neu cells were cultured in medias with lower glucose 




1% BCS) and reduced glucose (5mM and 2.5mM Glc) were compared to control (10% 
BCS/10mM Glc). Cells were maintained at 37C in a 5% humidified chamber. 
The human breast cancer cell lines SKBR3 (ATCC HTB-30) and BT-474 (ATCC 
HTB-20) derived from breast adenocarcinoma and ductal carcinoma, respectively, were 
cultured in RPMI 1640 (phenol free) supplemented with 10% fetal bovine serum (FBS), 
glucose (4.5g/L), HEPES buffer (10mM), sodium pyruvate (1mM), and 1% 
penicillin/streptomycin. To model nutrient restriction in vitro, serum levels were modified (5% 
and 1% FBS) and glucose concentration was reduced (5mM and 2.5mM Glc). Control media 
(10% FBS/ 10mM Glc) was used as the comparator.  
MTT assay 
MMTV/neu cells were seeded (2x103 cells/well) in a 96-well plate overnight, serum 
and/or glucose restricted for 24 hours, and then treated with one of the nutrient-restricted 
medias for an additional 24 hours. Media was aspirated and cells were incubated in a 
solution containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (0.5 
mg/mL) in PBS. After three hours, MTT reagent was aspirated and cells and precipitate 
were solubilized with dimethyl sulfoxide (DMSO) and agitation on a plate shaker for 5 
minutes. UV spectroscopy was used to measure absorbance at 570 and 690 nm via a 
Cytation 3 Cell Imaging Reader (BioTek). 
Cellular Proliferation 
MMTV/neu cells were seeded (2.5x104 cells/well) in a 6-well plate overnight and 
treated with nutrient restricted-medias as indicated. At treatment time intervals of 24, 48, 72, 
and 96 hours, cells were trypsinized (Trypsin-EDTA 0.05%, Gibco) and counted with a 
Countess II FL Automated Cell Counter (Thermo Fisher Scientific). 
Apoptosis Assay 
MMTV/neu cells were seeded (2.5x104 cells/well) in a 6-well plate overnight, serum 
and glucose starved for 24 hours, then treated with nutrient-restricted medias for an 




Apoptosis Kit for Flow Cytometry (ThermoFisher) according to the manufacturer’s protocol. 
Data was acquired using a BD Accuri C6 cytometer (BD Biosciences). Laser excitation at 
488nm was used to capture 30,000 events for each sample. PI fluorescence intensity was 
plotted against FITC fluorescence intensity. Live cells were categorized as PI and Annexin 
V-FITC negative, early apoptotic cells as Annexin V-FITC positive, and late apoptotic or 
dead cells as both PI and Annexin-V FITC positive. 
Cell Cycle Analysis 
MMTV/neu cells were seeded (2.5x104 cells/well) in a 6-well plate overnight and 
treated with either complete or nutrient-restricted medias for 24 hours. Cells were fixed, 
permeabilized, and stained with propidium iodide (PI) for flow cytometric analysis of cell 
cycle according to manufacturer’s instructions (Abcam). Single cells were analyzed using a 
CyAn ADP High-Performance Flow Cytometer (Beckman Coulter) and PI emissions were 
recorded at 488nm. Forward scatter and side scatter were assessed for 10,000 events and 
plots were gated to exclude cellular debris.  
Calcein-AM Live Cell Assay 
MMTV/neu (5x102 cells/well), SKBR3 (2x103 cells/well), and BT-474 (5x103cells/well) 
cells were seeded into black 96-well, clear bottom plates in complete media overnight. Cells 
were cultured in control or nutrient-restricted media as indicated for 48 hours (MMTV/neu) or 
72 hours (SKBR3 and BT-474). Following incubation, plates were centrifuged at 1,500 rpm 
for 5 minutes, media was aspirated, cells washed with PBS, and plates spun a second time. 
PBS was removed and cells were incubated in labeling solution containing the lipophilic 
reagent Calcein-AM (1M) dissolved in PBS for 40 minutes at room temperature. The 
fluorescent intensity of calcein was captured at an excitation/emission spectrum of 
490/520nm using a Cytation 3 Cell Imaging Reader (BioTek). The relative intensities 







Data were analyzed using GraphPad Prism 8 Software (GraphPad Software, Inc.). 
Differences between means were assessed using one-way analysis of variance (ANOVA) 
with post-hoc Tukey’s multiple comparison test for statistical differences. Data are 
graphically presented as mean ± standard error of mean (SEM) unless otherwise noted.  
Results 
Nutrient stress altered cellular viability and growth 
Examination of the phenotypic changes that occur in HER2-overexpressing breast 
cancer under conditions of nutrient stress was completed by comparing murine MMTV/neu 
cells cultured under control conditions (10% serum, 25 mM glucose) to those grown in 
serum (1% BCS)- or glucose-restricted (1mM Glc) media, or a combination of serum and 
glucose restriction (1% BCS and 1mM Glc, respectively), for 24 hours. Cellular viability was 
assessed via MTT viability assay, which measures the concentration of metabolically active 
cells in a given well. Following 24 hours of nutrient restriction, MMTV/neu cells cultured in 
reduced serum media had significantly decreased relative abundance of viable, 
metabolically active cells compared to cells cultured in complete media (Fig. 2A, 1% BCS 
p=0.02; 1% BCS and 1mM Glc, p=0.03). However, glucose restriction alone had a moderate 
non-statistically significant reduction in relative cellular viability during a 24-hour treatment 
period.  
Next, changes in cell number were examined under the same nutrient stress 
conditions by measuring the number of cells under various culture conditions over 24-hour 
intervals (Fig. 2B). The greatest differences in cell number compared to control were 
measured at 96 hours, as serum restriction (p=0.0002), glucose restriction (p=0.0013), and 
the combination of both (p=0.0003) significantly reduced cellular proliferation in vitro (Fig. 
2C) at that time point. Taking the findings from Figs 2A-2C together, the data suggest that 
reduced serum availability and (to a lesser extent) glucose restriction, induce a reduction in 




synergistic effect of combining serum and glucose restriction on viability or number of 
MMTV/neu HER2+ BC cells was observed. 
 
 
Figure 3. Nutrient stress altered HER2+ breast cancer cellular viability and 
proliferation 
MMTV/neu cells were cultured under control conditions (10% BCS and 25 mM glucose),  
serum restriction (1% BCS), glucose restriction (1mM glucose), or a combination of both 
(1% BCS and 1mM glucose). (A) Cellular viability following 24 hours of nutrient restriction 
was measured using an MTT viability assay (1% p=0.02; 1%/1mM p=0.03 vs. control). Data 
from n=4 experimental replicates is presented as mean ± SEM. (B) Number of cells in 
culture over 24-hour intervals in nutrient-restricted conditions. (C) Cell number following 96 
hours of culture. Serum restriction (p=0.0002), glucose restriction (p=0.0013), or the 
combination of both (p=0.0003) significantly reduced cellular proliferation in vitro relative to 
control conditions. Data from n=3 experimental replicates is presented as mean ± SEM. (B-

























































































































Serum restriction promoted cellular apoptosis 
To identify potential mechanisms through which cellular viability and proliferation are 
altered by nutrient stress, we next determined whether the reduced cell number in response 
to nutrient restriction observed in Figure 2 B-C was primarily due to cell death or to a 
reduction in the number of cells actively progressing through the cell cycle. We measured 
the proportion of apoptotic and dead cells relative to control in each of the treatment 
conditions previously described. Annexin V is a protein which efficiently binds 
phosphatidylserine that has translocated to the outer surface of the cell membrane, 
indicating the induction of apoptotic signaling, while propidium iodine (PI) is a nuclear dead 
cell stain that emits a red signal upon laser excitation. In this assay, annexin V was labeled 
with the fluorochrome FITC and Annexin V- and/or PI-positive cells were detected via flow 
cytometry (Fig. 3A). Quantification of the number of dead and apoptotic cells relative to 
control demonstrated that under nutrient-stressed conditions, serum restriction increased 
cellular apoptosis compared to control (Fig. 3B). Cells cultured in glucose-restricted media 




MMTV/neu cells were cultured in nutrient-restricted medias (control, 1% BCS, 1mM glucose, 
1% BCS and 1mM glucose) for 48 hours, and apoptotic cell death was measured using 
Annexin V/PI staining via flow cytometry. (A) Representative image of flow cytometry gating. 
(B) Percentage of dead and apoptotic cells following nutrient restricted conditions. Data from 
n=2 experimental replicates is presented with means.  
 
Serum restriction induced a G0/G1 arrest 
The impact of nutrient stress on cell cycle regulation was further explored by utilizing 
propidium iodine staining to quantify the proportion of cells in each phase of the cell cycle. In 
this assay, the proportion of propidium iodine staining correlates with the amount of DNA 
present in the cell, where two copies of each chromosome (2N) characterizes non-dividing 
cells, either senescent cells lacking replicative potential or cells in the G1 or G0 phases. 
Cells actively replicating DNA (2N-4N) are in the S phase. Following DNA replication, cells 
enter G2 or M phase (4N). Sharp peaks furthest left on histograms of forward scatter versus 
side scatter following propidium iodide staining are characteristic of the G1/G0 phase, and 
peaks shifting to the right correspond to the S and G2/M phases, respectively (Fig. 4A). 
Cells cultured in serum-restricted media experienced G0/G1 arrest compared to control (Fig. 




3B 1% p=0.0031; 1%/1mM p=0.0039). However, none of the nutrient restriction groups had 
significantly different portions of cells in the S or G2/M phases (Fig. 3B). 
 
Figure 5. Serum restriction induced G0/G1 arrest 
Cell cycle analysis of MMTV/neu cells cultured in serum- or glucose-restricted media. (A) 
Representative image of cell cycle flow cytometric analysis. (B) Frequency of cells in each 
phase of the cell cycle. Serum restriction induced G0/G1 arrest compared to control (1% 






Serum restriction reduced cellular viability in human and murine-derived HER2+ BC 
cell lines 
 
To increase the translational potential of these findings, the culture conditions were 
expanded to include human HER-positive cell lines (BT-474 and SKBR3), as well as more 
physiologically relevant glucose levels (5mM and 2.5mM Glc) and serum restriction 
concentrations (5% and 1%) than used in our previous experiments. The control group used 
for comparison was 10% serum/10mM glucose, as compared to the 10% serum/ 25mM 
glucose control used in the previously described experiments. In agreement with our initial, 
proof-of-concept findings, serum restriction to 1% reduced the number of live cells relative to 
control across the three breast cancer cell lines, as assessed using a calcein AM viability 
assay (Fig. 5A MMTV/neu p<0.0001; Fig. 5B BT-474 p=0.0002; Fig. 5C SKBR3 p<0.0001). 
Interestingly, an intermediate level of serum restriction (5% serum) decreased the live cell 
number only in BT-474 cells (Fig. 5B; p=0.0092). Surprisingly, limiting the glucose 
concentration in MMTV/neu cells to 2.5mM resulted in a greater number of live cells relative 
to control (Fig. 5D; p=0.0001). However, consistent with our initial findings using the 
MMTV/neu mouse cell line, human HER+ breast cancer cells did not demonstrate sensitivity 
to decreased glucose availability (Figure 5E-F). Together these results indicate that 
manipulation of glucose availability is less impactful on HER2+ BC survival and/or 
proliferation than limitation of other components found in serum, such as hormones, growth 





Figure 6. Serum restriction reduced cellular viability 
Murine- and human-derived HER2-positive breast cancer cells were treated with nutrient-
restricted media for 48 and 72 hours, respectively, and cell viability was assessed via 
calcein AM viability assay. Low-serum conditions reduced the number of live cells relative to 
control conditions (A) p<0.0001 (B) p=0.0092 (5%), p=0.0002 (10%) (C) p<0.0001. (D) 
Glucose restriction increased cellular viability in MMTV/neu cells (p=0.0001 2.5 mM vs 10 
mM). Technical replicates (n=3) graphically represented with mean ± SEM. 
 
Discussion 
In this study, an in vitro model of dietary restriction was developed to test the 
hypothesis that low-energy and/or nutrient availability underlies the in vivo sensitivity of 
breast cancer cells to dietary restriction. Murine MMTV/neu and human SKBR3 and BT-474 
cell lines were cultured under low glucose and serum conditions. It was determined that 
restriction of serum, but not restriction of glucose, results in reduced cellular metabolic 
activities and cellular viability. These changes were mediated through reduced cellular 








































































































































































































































































patterns. While these mechanisms were not confirmed in the human cell lines used in this 
study, the BT-474 and SKBR3 HER2-positive cell lines demonstrated similar patterns of 
reduced cellular viability in response to serum restriction, but not glucose restriction.  
Considering that the major components present in serum include proteins, vitamins, 
minerals, insulin and related growth factors, and major hormones for growth promotion, 
there are many different mechanisms through which reducing serum concentration in the 
media may have facilitated these changes. Of particular interest is reduced signaling 
through IGF1R and mTOR which occur in response to caloric restriction regimens. The 
nutrient-sensing IGF1R/mTOR pathway is stimulated by insulin and amino acids and plays 
an important role in stimulating growth and proliferation. Lamming, et al. found that mice on 
a protein restricted diet bearing ER+/PR-/HER2- breast tumor xenografts had decreased 
circulating amino acid levels and reduced phosphorylation of mTORC1 (32). Further, human 
studies have demonstrated the importance of modest protein restriction in a chronic CR 
regimen in order to modulate anti-cancer effects associated with decreased IGF1 levels 
(33). This highlights the importance of examining the impact of caloric restriction with 
respect to macronutrient composition of dietary regimen in vivo or corresponding mimetic in 
vitro. To test the hypothesis that reduced IGF1R activation under serum-restricted conditions 
is the primary driver of reduced cellular viability, future experiments will be conducted by 1) 
supplementing exogenous IGF1 to serum-restricted media and 2) using an anti-IGF1R 
antibody in complete serum conditions. We predict that HER2-positive breast cancer cells 
will not have reduced viability in the presence of exogenous IGF1 in serum-restricted media 
compared to control and that cells treated with an anti-IGF1R antibody will have reduced 
cellular viability, similar to cells treated with serum-restricted medias. 
In this study, we also found that serum restriction resulted in increased cellular 
apoptosis and dysregulation of cell cycle maintenance patterns. This agrees with the work of 




FBS, 0.5g/L glucose) had increased markers of DNA damage and cellular apoptosis (34). 
Similar results were found in vivo by Saleh, et al. in a model of triple-negative breast cancer 
which found that mice on a CR diet regimen had increased markers of apoptosis in tumor 
tissue, which was linked to downregulation of the IGF1 signaling pathway (35). These 
findings are consistent with previous in vivo studies suggesting dietary restriction achieved 
through chronic CR, intermittent fasting, or protein restriction rely in part on downregulation 
of IGF1 signaling to reduce cancer cell growth and proliferation. 
Further, in this study we found that alterations in cell viability and growth can be 
attributed to differences in cell cycle regulation impacted by nutrient stress. In cells cultured 
in serum-restricted medias, there was an accumulation of cells in the G0/G1 phase 
compared to control. Serum restriction may result in cell cycle arrest through induction of a 
stress response prompted by the lack of external growth factors that halts cellular 
proliferation. Serum restriction may also induce stress-induced senescence, a non-
proliferative, viable state.  However, additional studies will be needed to establish a role for 
cellular senescence, including  examination of morphological changes, activation of tumor 
suppressor pathways, and increased lysosomal B-D-galactosidase activity. 
In conclusion, our in vitro findings indicate that the sensitivity of HER2-positive breast 
cancer cells to dietary restriction may occur through reduction in the components present in 
serum, particularly IGF1. Further examination of pharmacological interventions that target 
metabolic pathways involved in growth factor signaling may provide a promising method of 





CHAPTER 3: METABOLIC REPROGRAMMING INTERVENTIONS IMPROVE RESPONSE 
TO LAPATINIB AND TRASTUZUMAB IN VITRO 
Background 
While dietary interventions in the form of fasting and fasting-mimicking regimens 
have demonstrated safety in clinical trials, there remains uncertainty regarding the 
feasibility of achieving compliance due to the potential discomfort and weight loss that 
accompanies dietary restriction. Therefore, a group of compounds that tolerably 
provides similar metabolic benefits without the challenges of strict dietary restriction and 
without causing potentially harmful adverse effects demonstrates an appealing clinical 
option. Combinations of pharmacological agents that target specific metabolic pathways 
that are altered in cancer cells , and that are reversed by dietary restriction, may provide 
a strategy to improve the sensitivity of cancer cells to therapies and overcome intrinsic 
and acquired drug resistance.  
Metabolic Reprogramming in Breast Cancer  
Cancer cells experience unique and dynamic shifts in their metabolic function in 
order to survive, proliferate, and evade growth inhibition in a resource-scarce environment. 
These metabolic changes can vary by, and are highly dependent on, the driver genetic 
mutations underlying specific cancer subtypes.  However, most cancer cells increase their 
glucose uptake, lipid synthesis, and glutaminolysis and switch glucose metabolism away 
from oxidative phosphorylation towards glycolysis when compared with normal cells. This 
allows for cancer cells to increase the biosynthesis of essential building blocks and 
manipulate substrates available in surrounding environment in order to increase tumor 
vascularization and survive (36). Breast cancers specifically reprogram their metabolic 




stimulate biosynthesis. While global patterns of metabolic aberrations are similar across 
different breast cancer subtypes, recent metabolomic analysis of primary breast tumors 
have demonstrated that each subtype preferentially drives metabolic fluxes through distinct 
pathways, which creates unique metabolic profiles (37). Of these distinctions, mechanisms 
that drive increased reliance on glucose and glutamine metabolism in HER2-overexpressing 
breast cancers are of particular interest. 
Breast cancer cells rely on high levels of flux through glycolysis accompanied by 
lactate secretion under aerobic conditions, known as the Warburg effect. Partially 
catabolizing glucose allows for cells to produce sufficient ATP while also reserving carbon 
intermediates that are shunted into anabolic pathways in order to sustain growth (38). This 
is achieved by increasing expression of the glucose transporters GLUT1 and GLUT4 to 
promote glucose uptake as well as overexpressing the glycolytic enzyme hexokinase 2 (39). 
Further, the SCF-Skp2 ubiquitin ligase increases activation of AKT which subsequently 
promotes activity of hexokinase and phosphofructokinase (40). In HER2-overexpressing 
breast cancer cells, metabolomic analyses have confirmed this reliance on glucose 
metabolism by the presence of high levels of fructose-1,6-bisphosphate, glucose-6-
phosphate, and pentose phosphate metabolites accumulated within cells (41). Signaling 
through the PI3K/AKT axis in breast cancer cells also promotes overexpression of 
monocarboxylate transporter 4 (MCT4), which is especially high in HER2-positive cell lines. 
MCT4 transports lactate across the plasma membrane, to maintain pH balance and 
regenerate cytosolic NAD to support proliferative activities and support survival in a hypoxic 
environment (42).  
In addition to high levels of glucose metabolism, HER2-positive breast cancers are 
also glutamine addicted. Compared to breast cancers of the luminal type, HER2-
overxpressing and triple negative breast cancers have the highest expression of proteins 
involved in glutamine metabolism (41). Breast cancer cells are able to increase utilization of 




transcription of glutamine transporters and glutaminase (GLS), which converts glutamate to 
glutamine. Mitochondrial glutaminolysis provides carbon substrates for entry into the 
tricarboxylic acid cycle (TCA) and nitrogen for amino acid synthesis (43). By recognizing the 
aberrant metabolic activities that breast cancer cells rely on to grow uncontrollably and resist 
apoptosis, therapeutic strategies can be developed with the goal of normalizing cellular 
metabolism and sensitizing cells to therapeutic interventions. 
 




Perturbing Glutamine Metabolism 
Given the dependency of HER2-positive breast cancer cells on glutamine metabolism for 
sustained growth, inhibitors of glutaminase and glutamine transporters have been developed. 
Bis-2-(5-pheylacetamido-1,2,4-thiadiazol-2-yl)ethyl (BPTES) is a small molecule glutaminase 
inhibitor that disrupts mitochondrial glutaminolysis (44).  Preclinical evaluation of BPTES in 
the luminal-like MCF7 and basal-like MDA-MB231 human breast cancer cell lines has 
revealed widespread metabolic alterations with its administration in vitro. Analysis of changes 
in metabolites demonstrated that BPTES alters flux through glycolysis, TCA cycle, and 
nucleotide biosynthesis pathways, which are modulated in hypoxic conditions (45). Another 
method of reducing glutamine utilization can be achieved by blocking mitochondrial uptake of 
glutamine. L-Glutamic acid γ-(p-nitroanilide) (GPNA) inhibits the glutamine transporter ASCT2 
and through off-target effects, competes with system L transporters to decrease uptake of 
essential amino acids, which in turn reduces the activity of mTORC1 (46).  
Perturbing Growth Factor Signaling 
IGF1 is a nutrient-sensitive endocrine hormone that is primarily secreted by the 
liver. Upon binding to its receptor (IGF1R), phosphorylation events lead to the activation 
of two signaling axes - MAPK and PI3K/AKT. This promotes increased cell proliferation 
and evasion of cell death (47, 48). Decreased levels of IGF1 in the fasted state are 
postulated to stimulate the potent anticancer effects of dietary restriction.  
In HER2-overexpressing breast cancers, one of the potential mechanisms of 
resistance to trastuzumab occurs through upregulation of IGF1R and subsequent cross-
phosphorylation and activation of HER2 (49). Therefore, blocking the activity of this 
receptor provides a useful strategy to improve drug response. BMS-754807 is a 
reversible inhibitor of insulin-like growth factor receptor 1 (IGF1R) and insulin receptor 
(IR). It has demonstrated effectiveness in decreasing signaling through MAPK and 
PI3K/AKT by competing with ATP for binding to the catalytic domain of IGF1R. BMS-




anticancer therapies to reduce cellular proliferation and induce apoptosis, as this IGF1R 
inhibitor has demonstrate effectiveness in vitro in combination with anti-cancer therapies 
for the treatments of breast, pancreatic, colon, lung, and gastric cancers (50).  
Further, the combination of an mTORC1 inhibitor, specifically the FDA-approved 
everolimus (RAD001), with HER2-directed therapies is also a promising approach to 
combat drug resistance. In drug resistant HER2-positive breast tumors, trastuzumab 
treatment increases phosphorylation of PDK1 and mTOR, which activates ribosomal 
protein S6 kinase beta-1 (S6K1) and promotes anabolic activities (51). Blocking this 
escape pathway with everolimus, a derivative of rapamycin that inhibits activation of 
mTORC1 by binding to FKBP12, is one approach to improve the efficacy of trastuzumab. 
Treatment with everolimus downregulates the nutrient-sensing effects of mTOR and 
results in reduced protein synthesis, cellular proliferation, and glucose uptake, as well 
as increased autophagic flux (52). In HER2-positive breast cancer patients treated with 
trastuzumab plus everolimus, serum metabolomic analysis revealed that this 
combination modulated a physiological state similar to that which occurs during fasting 
where lipolysis and autophagy are upregulated and gluconeogenesis and 
glycogenolysis are decreased (52).  
Autophagy in HER2-Positive Breast Cancer   
While the utilization of single-agent metabolic inhibitors in combination with anti-
cancer therapies has demonstrated promising preclinical benefits, the metabolic flexibility of 
cancer cells may provide an additional escape pathway through the induction of autophagy. 
In HER2-positive breast cancer, the precise role of autophagy in tumorigenesis and tumor 
progression is actively under investigation. Recent work has demonstrated that HER2-
positive breast cancer cells utilize lower levels of basal autophagy compared to HER2-
negative breast cancers under normal conditions, but under stressed conditions, induce 
autophagy to a greater extent. This is mediated in part through activation of ATG4B, a 




highlights the context-dependent manner through which this breast cancer selectively 
utilizes autophagy. Further, increased autophagy induction in response to treatment with the 
HER2-directed therapies trastuzumab and lapatinib has been implicated as a mechanism of 
drug resistance. Compared to trastuzumab-sensitive SKBR3 breast cancer cells, 
trastuzumab-resistant JIMT-1 cells constitutively utilize higher levels of autophagy in order to 
sustain proliferative activities (54).  Similarly, treatment of HER2-positive cells with lapatinib 
has also been show to increase autophagy induction, which if sustained, can allow cells to 
survive and develop drug-resistance (55-57). However, the role of autophagy in promoting 
cell survival in the presence of HER2-directed therapies remains controversial. A recent 
study by Vega-Rubin-de-Celis, et al. demonstrated a novel mechanism of autophagy 
suppression via HER2 interaction with Beclin1 (BECN1) a key autophagy protein that 
promotes autophagosome initiation under starvation conditions. This is significant because 
HER2-positive breast cancer patients with allelic loss of BECN1 have worse clinical 
prognosis, implicating that suppression of autophagy through this interaction may have pro-
tumorigenic effects (58). Further, disruption of this interaction using a small molecule, Tat-
Beclin 1, in mice bearing BT-474-VH2 xenografts resulted in increased autophagy induction 
and reduced tumor progression as effectively as treatment with lapatinib (58). These studies 
highlight the context-dependent role of autophagy and the importance of conducting 
autophagic flux analysis with interventions that target HER2-positive breast cancer. 
 Perturbing cancer cell metabolism by targeting growth factor signaling and glutamine 
metabolism is capable of stimulating autophagy, therefore, the FDA approved autophagy 
inhibitor, chloroquine (CQ), is used in combination with  the aforementioned agents. 
Chloroquine blocks endosomal acidification and disrupts the maturation of the 
autophagolysosome (59). Autophagy is primarily regulated by PI3K/mTOR, therefore under 
low-energy conditions modulated by nutrient stress of pharmacologic inhibition of energy-




by MRIs would stimulate autophagy, therefore combining them with chloroquine could 
potentially block this escape pathway. 
Methods 
In Vitro Dose Selection and Combination Assays using Metabolic Reprogramming 
Interventions and HER2-directed Therapies 
 
For lapatinib/serum restriction combination assays, MMTV/neu cells (1x103 
cells/well) were seeded into black 96-well, clear bottom plates in complete media overnight. 
Cells then cultured in control (10%BCS/ 10mM Glc) media and reduced serum (5% and 1% 
BCS/10mM Glc) medias with lapatinib (EC50 = 10M) or DMSO vehicle for 48 hours. 
Following incubation, calcein emission was measured (see chapter 2 methods). 
For metabolic reprogramming intervention assays, MMTV/neu cells (5x102 cells/well) 
were seeded into black 96-well, clear bottom plates in complete DMEM overnight. Dose 
selection curves were completed using the following metabolic reprogramming interventions 
(MRI) in low-glucose DMEM (5.5mM) for 48 hours: lapatinib (Selleckchem), l-γ-glutamyl-p-
nitroanilide (GPNA; Sigma-Aldrich), Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl 
sulfide 3 (BPTES; MedChemExpress), sodium oxamate (Sigma-Aldrich), 3-bromopyruvate 
(Sigma-Aldrich), chloroquine (Sigma-Aldrich), everolimus (MedChemExpress), BMS-754807 
(Selleckchem). Drug dosages that resulted in approximately 30 percent growth inhibition 
were selected and used for treatments in combination with lapatinib (EC30 = 5M) and 
chloroquine (EC30 = 2M).  
BT-474 cells (5x103 cells/well) were seeded into black 96-well, clear bottom plates in 
complete RPMI media overnight. Dose selection curves were completed on the following 
compounds in low-glucose RPMI (5.5mM) for 72 hours: BPTES (MedChemExpress), 
chloroquine (Sigma-Aldrich), everolimus (MedChemExpress), BMS-754807 (Selleckchem). 
Calcein AM Live cell staining (see Methods, Chapter 2) was used to assess the relative 




inhibition were selected and used for treatments in combination with Trastuzumab 
(10ng/mL) and chloroquine (EC30 = 10M).  
Western Blotting to Confirm Target Inhibition 
To confirm target inhibition following treatment with trastuzumab, BT-474 cells (5x105 
cells/well) were seeded into 6-well plates overnight to reach 70% confluence. Cells were 
gently washed with PBS and treated with complete (10% BCS/ 5.5mM Glc) or serum free 
media (5.5mM Glc) containing Trastuzumab (10ng/mL, Selleckchem) or vehicle (PBS) for 4 
hours. Whole cell lysates were generated using RIPA lysis buffer (Sigma Aldrich) 
supplemented with protease inhibitor cocktail (Sigma Aldrich). Cells scraped from dish and 
incubated on ice for 10 minutes. Cellular debris separated via centrifugation at 14000 RPM 
for 15 minutes at 4C and the protein-containing supernatant was collected. Protein 
concentration was determined via Bradford protein quantification assay. Protein lysates 
denatured by boiling for 5 minutes at 95 °C in solution containing Loading Buffer (Biorad) 
and 5% -mercaptoethanol (BME). Protein separated via SDS-PAGE and transferred to 
PVD membrane for western immunoblotting. Membranes blocked at room temperature for 1 
hour in Tris-buffered saline containing 0.1% Tween (TBST) and 5% Bovine Serum Albumin. 
Membranes were incubated with primary antibody overnight at 4C, washed with TBST, and 
blocked in secondary antibody for 1 hour at room temperature. Chemiluminescent detection 
utilized with SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Fisher). 
Images generated with the ChemiDoc XRS+ System (Biorad). Images analyzed using 
ImageJ software according to NIH gel analysis procedures. BT-474 (5x105 cells/well) and 
MMTV/neu cells (2.5x105/well) were seeded into 6-well plates overnight to reach 70% 
confluence. Cells were gently washed with PBS and treated for 4 hours with complete or 
serum-free media controls and a single dose of chloroquine, BMS-754807, everolimus, or 
BPTES corresponding to the EC30 for each cell line as described above (doses indicated in 




#9101, 1:1000), p-IGF1R/IR Tyr 1135/1136 (CST #3024, 1:1000), p-S6 Ser 235/236 (CST 
#2211, 1:1000), LC3B (CST #2775, 1:1000), -Tubulin (CST #2146, 1:2000), -Actin (CST 
#4970, 1:2000).  
Statistical Analysis 
Data were analyzed using GraphPad Prism 8 Software (GraphPad Software, Inc.). 
Differences between means were assessed using one-way analysis of variance (ANOVA) 
with Tukey’s multiple comparisons for statistical differences. Data graphically presented as 
mean ± standard error of mean (SEM) unless otherwise noted.  
Results 
Serum restriction decreased cellular viability in combination with HER2-directed 
therapies 
 
Having determined that restricting serum availability in vitro decreases cellular 
viability and growth in HER2-positive breast cancer cells, it was posited that serum 
restriction in combination with HER2-directed therapies would enhance growth inhibition to a 
greater extent than the therapy alone. Since trastuzumab is a humanized monoclonal 
antibody, this drug is only effective against the human HER2 receptor, not the rat homolog, 
neu. Therefore, lapatinib was selected as the HER-2 directed therapy for the murine-derived 
MMTV/neu cell line and trastuzumab with the BT-474 cell line.  
MMTV/neu cells were treated with serum restricted medias plus lapatinib (10μM) for 
48 hours. Compared to the lapatinib treated cells cultured in complete media (10mm/10% 
BCS) that experienced ~50% growth inhibition, cells treated with lapatinib in serum 
restricted media had significantly increased growth inhibition. This effect was strengthened 
in a concentration-dependent manner, where greater reductions in the proportion of serum 
available in media increased the growth inhibitory effect of lapatinib (Fig. 7B p=0.0005 10% 
vs. 5%; p<0.0001 10% vs. 1%; p=0.0080 5% vs. 1%). However, when BT-474 cells were 




confirmation of target inhibition (Fig. 8A, B), there were no statistically significant differences 
in growth inhibition under serum restricted conditions relative to control (Fig. 8C).  
 
 
Figure 8. Serum restriction increased growth inhibitory effect of lapatinib 
(A) MMTV/neu cells were treated with lapatinib (1.5-50μM) for 24 hours in complete low 
glucose DMEM (5.5mM Glc/10% BCS). Treated cells were normalized to vehicle control. 
Data from n=3 experiments is presented as mean ± SEM (EC50 = 17.16μM, EC30 ~ 10μM). 
(B) MMTV/neu cells treated with vehicle or 10μM lapatinib in complete or serum-restricted 
media for 48 hours. Treated cells were normalized to vehicle control (10mM/10%BCS + 
0.1% DMSO). Data from n=3 experiments is presented as mean ± SEM. One-way ANOVA 
with Tukey’s multiple comparisons. Serum restriction increased the growth inhibitory effect 
of lapatinib in a concentration-dependent manner (p=0.0005 10% vs. 5%; p<0.0001 10% vs. 
1%; p=0.0080 5% vs. 1%). 





























































Figure 9. Efficacy of trastuzumab was not improved by serum restriction 
 (A) BT-474 cells treated with complete media (CON) or serum starved (SS) with or without 
trastuzumab (TZB; 10ng/mL) for 4 hours. Protein lysates collected and relative abundance 
of phosphorylated Erk (p-Erk) normalized to tubulin loading control measured via western 
blotting. (B) Fold change in p-Erk in each treatment group compared to control plotted. 
Biological replicates plotted mean ± SEM (n=3) (SS p=0.0429; CON+TZB p=0.0005; 
SS+TZB p=0.0016). (C) BT-474 cells treated with serum restricted medias plus 10ng/mL 
trastuzumab for 72 hours. Technical replicates normalized to control in complete media 




Metabolic reprogramming interventions modified activation of downstream targets 
In order to confirm that the metabolic reprogramming interventions selected 
effectively modulated anticipated protein targets at the EC30 dose in each cell line, western 
blotting was used to examine the abundance of downstream targets following short-term 
incubation with each compound. Treatment with the dual IGF1R/IR inhibitor BMS-754807 
decreased phosphorylation of IGF1R in MMTV/neu (Fig.9A; p=0.0238) and in BT-474 cells 
(Fig. 9B; n=1). To determine the specificity of the mTORC1 inhibitor everolimus, 
phosphorylation of ribosomal protein S6 (p-S6) was measured. When mTOR is active, 
signaling occurs through ribosomal protein S6 kinase beta-1 (S6K1), which phosphorylates 
S6. In the HER2-positive cell lines treated with everolimus, phosphorylated S6 was 
undetectable compared to control, indicating that the selected dose of this drug effectively 
impairs mTORC1 downstream signaling (Fig. 9C p<0.0001; Fig. 9D p<0.0001).  
It was postulated that selectively targeting growth factor-associated signaling 
pathways with these interventions would stimulate a cellular stress response and 
subsequently induce increased autophagic flux (61). LC3II abundance was measured, which 
is a proxy for the number of autophagosomes present in the cells under different treatment 
conditions. However, none of the MRI treatment conditions resulted in increased LC3II 
accumulation in MMTV/neu or BT-474 cells (Fig. 9E; Fig. 9F). The lack of LC3II 
accumulation may be due to a lack of autophagic response or, alternatively, unchanged 


























































































































































































































































































Figure 10. Target inhibition was achieved with MRIs 
Modulation of protein targets in MMTV/neu and BT-474 cells treated with BMS-754807, 
everolimus, and BPTES for 4 hours with the EC30 dose confirmed via western blotting. 
Complete media (CON) and serum starvation (SS) serve as controls for all experiments. 
Protein abundance was normalized to loading control and represented as fold change 
relative to control. BMS-754807 (100nM) inhibited phosphorylation of IGF1R in (A) 
MMTV/neu cells (p=0.0238) and (B) BT-474 cells. Everolimus (100nM) blocked activation of 
downstream mTOR protein S6 ribosomal protein (p-S6) in (C) MMTV/neu cells (p<0.0001) 
and (D) BT-474 cells (p<0.0001). LC3II was increased under serum-starved conditions in (E) 
MMTV/neu cells (p=0.0058), but no significant changes were detected in (F) BT-474 cells. 
Representative western blots from n=1 experiment shown for (G) MMTV/neu cells and (H) 
BT-474 cells. Data shown from n=3 experimental replicates for MMTV/neu cell line, n= 1-3 
experimental replicates for BT-474 cell line. Data presented as mean ± SEM. 
 
Inhibition of IGF1R and mTOR increased efficacy of lapatinib 
In response to the HER2-directed therapy lapatinib, HER2-positive BC cells 
upregulate several pathways those involved in the glucose deprivation network and the 
mTOR signaling axis. It was postulated that enhanced growth inhibition could be achieved 
with the combination of MRIs that target these pathways. Since these drugs have the 
potential to induce autophagy given their mechanistic targets, triple combinations of these 
compounds with chloroquine were also examined. Of the compounds tested, inhibition of 
IGF1R/IR with BMS and mTORC1 with everolimus demonstrated significantly increased 
growth inhibitory effects in combination with lapatinib relative to lapatinib treatment alone 
(Fig. 10A, p<0.0001; Fig. 10B, p=0.0192). However, addition of chloroquine to these 
regimens did not meaningfully increase growth inhibition beyond that achieved by the dual 




inhibitor, BPTES, to lapatinib treatment also did not significantly improve growth inhibition, 




Figure 11. MRIs in combination with lapatinib 
MMTV/neu cells were treated with EC30 dose of lapatinib, chloroquine, or metabolic 
reprogramming interventions (BMS-754807 (BMS), everolimus, and BPTES, singly or in 
dual or triple combinations for 48 hours. Data from n=3 experimental replicates is presented 
as mean ± SEM. (A) The addition of BMS to lapatinib treatment significantly reduced cellular 
viability compared to lapatinib alone (p<0.0001). (B) Addition of everolimus to lapatinib 
treatment reduced viability compared to lapatinib alone (p=0.0192). (C) Addition of BPTES 
to lapatinib treatment did not meaningfully increase growth inhibition in a dual combination 
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Dual inhibition of mTORC1 and autophagy increased efficacy of trastuzumab  
The metabolic reprogramming agents aforementioned were next combined with 
trastuzumab in BT-474 cells to determine if enhanced growth inhibition could be achieved 
with these agents. Contrary to the increased growth inhibition that occurred with dual 
treatment of BMS and lapatinib in MMTV/neu cells, the combination of BMS and 
trastuzumab did not significantly increase growth inhibition compared to either agent alone, 
even with the addition of chloroquine (Fig. 11A). Of the combinations explored with 
trastuzumab in BT-474 cells, only the addition of everolimus and chloroquine to trastuzumab 
treatment was more effective than trastuzumab alone (Fig. 11B p<0.0001). However, this 
likely occurred independently of trastuzumab as the dual combination of everolimus and 
chloroquine inhibited growth to a degree similar to the triple combination and was more 
effective than any single agent (Fig. 11B, p<0.0001 vs. trastuzumab; p<0.0001 vs. 
everolimus; p=0.0317 vs. chloroquine). Similar to the results in MMTV/neu cells, the addition 
of BPTES to trastuzumab treatment in BT-474 cells did not meaningfully increase growth 







Figure 12. MRIs in combination with trastuzumab 
BT-474 cells were treated with EC30 dose of trastuzumab, chloroquine, or metabolic 
reprogramming interventions (BMS-754807 (BMS), everolimus, and BPTES), singly or in 
dual or triple combinations for 72 hours. Data from n=3 experimental replicates is presented 
as mean ± SEM. (A) Addition of BMS-754807 (BMS) to treatment with trastuzumab did not 
significantly increase growth inhibition compared to trastuzumab alone, even with the 
addition of chloroquine. (B) Compared to trastuzumab treatment alone, addition of 
everolimus did not significantly increase growth inhibition (p=0.0991). The combination of 
everolimus and chloroquine resulted in significantly increased growth inhibition compared to 
any single agent (p<0.0001 v. trastuzumab; p<0.0001 v. everolimus; p=0.0317 v. 
chloroquine). The triple combination of trastuzumab with chloroquine plus everolimus 
significantly increased growth inhibition compared to trastuzumab treatment alone 
(p<0.0001), but was not more effective than chloroquine plus everolimus without 
trastuzumab (p=0.8407). (C) The addition of BPTES to treatment with trastuzumab did not 
meaningfully increase growth inhibition compared to trastuzumab alone (p=0.9477), nor did 
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Here we demonstrated that modulation of energy-responsive pathways through 
either serum restriction, which models caloric restriction in vitro, or metabolic reprogramming 
interventions, has the potential to increase the antiproliferative effect of lapatinib. Our finding 
that lapatinib treatment in reduced serum conditions decreases cellular viability to a greater 
extent than with treatment in complete media agrees with the work of Caffa et. al. which 
demonstrated that SKBR3 and BT474 cells cultured in starvation conditions (0.5g/L glucose, 
1% serum) had increased antiproliferative effects of lapatinib compared to control (62). It is 
plausible that inducing a low-energy state with serum restriction decreases signaling through 
PI3K/AKT, and prevents compensatory mechanisms that are activated in response to 
lapatinib treatment, thereby more effectively reducing cellular viability. This finding was used 
to inform our current in vivo model which aims to increase the efficacy of lapatinib and 
trastuzumab by restricting food adjuvant to therapy administration in 48-hour intermittent 
fasting cycles. While the preliminary data did not support that serum restriction increases the 
antiproliferative effect of trastuzumab in vitro, an animal model with an intact immune system 
is necessary to fully address this hypothesis with an intact immune system. Short-term 
fasting has been demonstrated to enhance tumor immunosurveillance, which is crucial for 
the antibody-dependent cellular cytotoxicity function of trastuzumab (63).  
Further, targeting metabolic pathways implicated in HER2-directed therapeutic 
resistance through metabolic reprogramming interventions, specifically inhibition of 
IGF1R/IR and mTOR demonstrated effectiveness in combination with lapatinib. This is in 
agreement with studies that have treated BT-474 and ZR-75-30 cell lines (HER2+/ER+), 
with a combination of trastuzumab, BMS-754807, and neratinib (a TKI of pan-HER family 
receptors), and demonstrated that increased cell death occurs compared to trastuzumab or 
neratinib alone (49). Similarly, inhibiting IGF1R with the agent AEW541 elicited potent anti-




with BT-474 tumors (25). However, our approach was novel in combining inhibition of HER2 
and IGF1R/IR with a transient autophagy inhibitor. We did not find that the addition of 
chloroquine increased the growth-inhibitory effect of BMS-754807 with either lapatinib or 
trastuzumab. Similarly, treatment with everolimus increased the growth-inhibitory effect of 
lapatinib, but this effect was not strengthened with the addition of chloroquine. In order to 
explore this mechanism further, it should be determined if the combination of IGF1R/IR or 
mTOR and HER2 inhibition increases autophagic flux. This could be done by transducing 
HER2-positive cell lines with a lentivirus that permits visualization of autophagosomes and 
autolysomes in order to measure autophagic flux. Further, if autophagy is upregulated from 
baseline levels with BMS or everolimus treatment, experiments should also be conducted 
with higher doses of chloroquine in combination with these MRIs and HER-directed drugs to 
determine if a synergistic effect can be achieved with these compounds.  
 Another major limitation in the MRI experiments was the use of BPTES as the 
glutaminase inhibitor. Relatively high doses of this drug in the micromolar range were 
required for an effect to occur, raising the concern of potential off-target effects. Future 
experiments should be conducted using a glutaminase inhibitor with higher specificity such 
as the agent CB-839 which is already being used in clinical trials for different cancer 
subtypes. In triple negative breast cancers, which are also glutamine-addicted, combination 
of CB-839 with the chemotherapies cisplatin and etoposide reduced cellular proliferation and 
increased apoptosis (64). This indicates that our findings with BPTES may not capture the 
full potential of combining glutaminase inhibition with HER2-directed therapies. 
However, this project is effective in informing future experiments that will determine if 
combinations of everolimus and BMS are able to re-sensitize drug-resistant HER2-positive 
cell lines to therapy. Lapatinib-resistant SKBR3 and BT-474 cell lines will be treated with 
combinations of everolimus, BMS, lapatinib, and chloroquine to determine if these agents 




determined using live cell assays and clonogenicity will be measured using colony formation 
assays. It is postulated that these MRIs will be effective in achieving this goal as 
combination of everolimus with trastuzumab in HER-positive, drug-resistant advanced 
breast cancer improved progression free survival to 7.00 months vs. 5.78 months in 
trastuzumab in a phase III clinical trial (65). However, it has not yet been determined if the 
addition of chloroquine to this regimen has the potential to increase drug efficacy. We 
hypothesize that chloroquine will improve drug response because previous studies in 
lapatinib-resistant BT-474 cells have demonstrated that transient inhibition of autophagy 
with chloroquine re-sensitized cells to lapatinib by synergistically promoting apoptosis and 
reducing cell proliferation (57). Together, these studies highlight the potential of combining 
MRIs with chloroquine in lapatinib-resistant cells to improve drug response.  
Together, this study identified BMS and everolimus as efficacious metabolic 
reprogramming interventions that improve therapeutic response to lapatinib in HER2-






CHAPTER 4: ONGOING AND PLANNED STUDIES – IMPACT OF INTERMITTENT 
FASTING REGIMENS ON TUMOR PROGRESSION AND RESPONSE TO HER2-
DIRECTED THEAPIES IN VIVO 
Background 
Metabolic Impact of Dietary Restriction 
Dietary restriction (DR), which broadly encompasses a variety of caloric restriction 
regimens, has been demonstrated to promote longevity and reduce tumor growth across 
multiple breast cancer molecular subtypes (66). For example, chronic calorie restriction 
(CR), or dietary energy restriction by 20-40%, has demonstrated tumor suppressive effects 
in breast, colon, and pancreatic (30, 63, 67). Proposed mechanisms include enhanced 
apoptosis within tumors, reduced angiogenesis, and alterations in key metabolites and 
systemic signaling pathways involving IGF1, mTOR, and AMP (48). While its beneficial 
effects have been well-defined in the context of continuous energy restriction, a more 
translational approach may be achieved through cycles of acute dietary restriction centered 
around the administration of anti-cancer therapy.   
Fasting protocols indicate that subjects voluntarily abstain from solid food for brief 
intervals of time while consuming water alone or, in the case of partial fasting regimens, 
consume vegetable broths and fruit juices (250-500 kcal/day) (68). The safety of completely 
abstaining from food for periods of 2 or more days has been demonstrated in a medically-
supervised setting and indicates that the majority of healthy patients experience minimal 
adverse reactions (69).  
Broadly, fasting is postulated to promote the fitness of model organisms by improving 
adaptation to cellular stress and by reducing exposure to oxidative stress which in turn 
improves mitochondrial health. By modulating the activities of the nutrient-sensing metabolic 




During periods of fasting, serum glucose levels decrease, and hepatic glycogen stores 
diminish within 24 hours (66). Alternative metabolic pathways are upregulated to provide 
substrates to energy utilization. Gluconeogenesis is engaged to provide glucose to specific 
tissues, primarily the brain, and β-oxidation is upregulated to harness energy from free-fatty 
acids released from adipose tissue. The ketone bodies β-hydroxybutyrate and acetoacetate, 
released as a byproduct of β-oxidation and from the conversion of ketogenic amino acids, 
are utilized in the process of ketolysis (66).  
In rodents, fasting and caloric restriction modulate similar metabolic targets, but elicit 
distinct physiological responses (71). During a 48 hour fast, rodents experience weight loss 
of approximately 20 percent, compared to a 4 day fast in humans which causes less than 2 
percent weight loss (72). Within a 48-hour fasting period, rodents experience a decrease in 
blood glucose by ~50 percent (73). While blood glucose levels in humans decrease after two 
days in the fasted state, clinically acceptable glucose levels are maintained within this period 
(74). Additionally, in humans and mice, IGF1 levels decrease by 40 and 70 percent 
respectively during periods of fasting ranging from 24 to 72 hours.  Alternatively, IGF1 
decreases by 15 to 25 percent with continuous caloric restriction (71). Another key 
mechanism through which dietary restriction may have its anticancer effects it’s through 
autophagy induction. During fasting periods of 12 to 24 hours, mice have increased 
induction of autophagy which may be mediated through sirtuin-1 mediated deacetylation of 
key autophagy proteins including ATG5, ATG7, ATG12, and LC3, as well as decreased 
signaling through the PI3K/mTOR axis (75-77).  
Intermittent Fasting 
A variety of short-term fasting protocols have been developed to augment chemotherapy 
cycles including intermittent fasting, periodic fasting, and fasting-mimicking diets (78). Unlike 
intermittent fasting, periodic fasting regimens last for 3 days or longer and are repeated 
every 2 or more weeks and fasting-mimicking regimens use a plant-based, calorie-restricted, 




Intermittent fasting regimens involve cycles of short-term partial or complete caloric 
restriction in intervals ranging from 1 to 3 days per week. This method encompasses 
protocols for whole-day fasting, time-restricted feeding, and alternate-day fasting (79). 
Whole day fasting indicates total caloric restriction for periods ranging for 24 to 48 hours per 
week, either consecutively or nonconsecutively with ad libitum feeding on remaining days 
(79). Time-restricted feeding regimens define consecutive periods of ad libitum feeding that 
range from 3 to 12 hours per day followed by complete dietary restriction. Alternatively, 
intermittent fasting can be achieved through alternate day fasting or by following the 5:2 diet. 
In protocols for the 5:2 diet, caloric consumption is restricted to approximately 25% of 
energetic needs on scheduled non-consecutive fasting days with ad libitum feeding on the 
remaining days of the feeding cycle (80). While these protocols vary in the indicated feeding 
schedule, human studies have demonstrated that adherence promotes metabolic 
enhancements including decreased serum concentration of triglycerides, glucose, and low-
density lipoprotein cholesterol (81). 
In mice, intermittent fasting regimens are modeled by completely restricting food for 
approximately 24 hours every 5 to 7 days (66). In an animal model, this intervention is 
demonstrated to be as effective as continuous caloric restriction in decreasing fasting insulin 
and glucose concentrations, as well as reducing total plasma cholesterol and triglycerides 
(82). In mice, examination of a regimen that restricted calories by 85% on alternate fasting 
days found decreases in IGF1, leptin, and visceral fat, and increased levels of adiponectin 
(83). Human studies have demonstrated that adherence to these protocols promotes 
modest weight loss and reductions in total plasma cholesterol and triglyceride 
concentrations (84, 85). However, in human studies conducted on individuals that were 
overweight or obese for periods of 8 weeks to 6 months, intermittent fasting regimens have 
not consistently been demonstrated to improve insulin and glucose control (80). However, 
one studied that compared of the metabolic impact of intermittent caloric restriction (2 days 




premenopausal women demonstrated that intermittent caloric restriction resulted in a 
greater reduction in fasting insulin levels and insulin resistance compared to continuous 
energy restriction. In both interventions, similar decreases in leptin, C-reactive protein, LDL 
cholesterol, and triglycerides were achieved, but, the differences in glycemic control that 
followed adherence to each respective regimen indicates that different mechanisms may be 
driving the metabolic alterations (86). 
Fasting and Anti-Cancer Therapy   
It is postulated that fasting and fasting-mimicking regimens target distinct metabolic 
pathways in cancer cells versus non-transformed cells, eliciting differential response to 
treatment with chemotherapy. Compared to oncogene-driven cells, non-transformed cells 
exposed to short-term starvation enter a chemo-protective state characterized by decreased 
cellular division and increased utilization of repair pathways, termed the differential stress 
resistance (87, 88). This has significant implications for reducing the cytotoxicity associated 
with chemotherapy. Conversely, malignant cells are selectively sensitized to 
chemotherapeutics by bouts of short-term fasting, termed differential stress-sensitization 
where cancer cells are preferentially destroyed by chemotherapy (89). In response to fasting 
and fast-mimicking diets, normal cells down regulate protumorigenic pathways (mTOR, 
PKA, AKT, IGF1), which reduces growth and induces protection against the cytotoxic effects 
of chemotherapies. Cancer cells, which constitutively upregulate these protumorigenic 
pathways due to oncogene activation, are unable to decrease flux these pathways rendering 




Animal Design Protocol 
MMTV/neu Pilot Study 
To determine the growth trajectory of MMTV/neu breast cancer cells in a tumor 
transplant model, 1x106 cells/50uL were orthotopically injected into the 4th mammary fat pad 
of female wildtype FVB mice (n=6) or transgenic FVB/N-Tg(MMTVneu)202Mul/J mice 
(Jackson Laboratory) (n=12). FVB mice received cells in a 1:1 ratio PBS and Matrigel. 
Transgenic FVB/N-Tg(MMTVneu)202Mul/J mice received either cells in a solution of PBS 
(n=6) or a 1:1 ratio of PBS with Matrigel (Corning). Tumor palpations were conducted 
biweekly for 16 weeks post-injection until mice developed tumors that were 1.5 cm in any 
direction.  
Lentiviral Transduction 
The MMTV/neu transgenic mouse spontaneously generates tumors at 6 months of 
age, therefore orthotopically injected tumor cells were tagged with a construct that 
expresses luciferase in order to distinguish the transplanted tumors from any potential 
spontaneously generated tumors. MMTV/neu cells were transduced with a firefly luciferase 
lentivirus (KeraFAST) according to manufacturer’s protocol. Transduction results in 
intracellular production of firefly luciferase, an enzymatic product capable of oxidizing 
luciferin and generating a bioluminescence reaction for detection with IVIS imaging. 
Transduced cells were selected with puromycin (5g/mL) and maintained in DMEM 
supplemented with 10% BCS and puromycin (2g/mL).  
MMTV/neu mouse model` 
Seven to eight-week-old FVB/N-Tg(MMTVneu)202Mul/J mice (Jackson Laboratory) 
were acclimated for two weeks on a low-fat control diet (10 percent kcal/fat; Research Diets 
D12450J). Mice received an orthotopic injection of the luciferase-expressing MMTV/neu 
breast cancer cell line (2x106 cells/50uL) into the fourth mammary fat pad. Biweekly 




used to calculate approximate tumor volume (90). Upon development of tumors of 
appropriate size (100mm3), mice were randomized to one of four treatment groups 
(n=18/group): 1) Lapatinib, 2) Vehicle, 3) Lapatinib + 48-hour fast, or 4) Vehicle + 48-hour 
fast. In the non-fasting groups, Lapatinib (100mg/kg) or Vehicle was administered 6 
days/week for three weeks(91, 92). In the fasting groups, mice were fasted for 48-hours 
total, beginning 24-hours prior to initiation of treatment with Lapatinib or vehicle and ending 
24-hours following initiation, with a total of 6 days of Lapatinib or Vehicle treatment/week.  
Mice euthanized following 3 weeks of therapy or when a tumor endpoint of 1.5 cm in 
diameter was reached.  
Body Composition Measurements 
Body composition measurements will be taken at baseline, when MMTV/neu mice 
reach a tumor volume of 100mm3, and again at study endpoint via Magnetic Resonance 
Imaging (MRI) conducted by the UNC Animal Metabolism Phenotyping Core.  
In Vivo Bioluminescent Imaging 
Once mice reach an appropriate tumor volume to initiate therapy (100mm3), In Vivo 
Imaging System (IVIS) will be used to confirm the presence of the transplanted tumors in the 
mammary fat pad rather than spontaneously developed tumors. Ten minutes prior to 
imaging, mice will be anesthetized with isoflurane and the luciferin substrate (150mg/kg, 
Sigma-Aldrich) will be administered. Mice imaged using IVIS Lumina Imaging System 
(Perkin Elmer).  
BT-474 Mouse Model 
Eight-week old athymic nude (nu/nu) mice acclimated for 1 week on a low-fat control 
diet (Control, 10 percent kcal from fat, Research Diets D12450J). Mice were anesthetized 
with isoflurane for implantation of 17-b-estradiol (0.36 mg, 90-day release) pellets three days 
prior to tumor cell inoculation. BT-474 (ATCC HTB-20) cells derived from human ductal 
carcinoma were orthotopically injected into the 4th mammary fat pad (5x106 cells/50uL) in 




measure tumor size and the formula V = (W(2) × L)/2 was used to calculate approximate 
tumor volume (90). Upon development of tumors of appropriate size (100mm3), mice were 
randomized to one of four treatment groups (n=21 /group): 1) Trastuzumab, 2) Vehicle, 3) 
Trastuzumab + 48-hour fast, or 4) Vehicle + 48-hour fast. Tumors palpated twice weekly. 
Mice were given Trastuzumab (5 mg/kg) or vehicle via intraperitoneal (IP) injection 1 
day/week for three weeks(92-94). In the fasting groups, mice were fasted for 48-hours total, 
starting 24-hours prior to initiation of Trastuzumab or vehicle treatment and ending 24-hours 
after initiation. Mice euthanized following 3 weeks of therapy or when a tumor endpoint of 






Figure 13. MMTV/neu mouse study pilot and design 
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 Upon completion of this study, several key analyses will be completed. Weights of 
mice will be collected throughout the fasting period in order to determine the amount of 
weight lost during fasting and the time required for mice to regain weight to baseline levels. 
In the MMTV/neu mouse model, body composition measurements will be taken via magnetic 
resonance imaging prior to therapy administration and at study endpoint. Together, data on 
body weight maintenance patterns and body composition will allow us to determine whether 
fat mass and/or lean mass is modulated by fasting. In the nu/nu mouse model, circulating 
estrogen levels will be measured via Elisa assay from samples taken in a cohort of mice 
post-implantation of estradiol pellets. This will allow us to confirm that the appropriate 
estrogen levels were established in order to maintain growth of BT-474 tumors. Prior to each 
interim sacrifice and at study endpoint, blood glucose measurements will also be collected in 
order to compare changes in glucose levels both during a fasting period and upon refeeding. 
Serum collected during the interim sacrifice and at study endpoint will be used to measure 
levels of insulin, leptin, major cytokines and inflammatory markers. Tumors will be excised 
and weighed during interim sacrifice and at study endpoint. Following collection of tumor 
tissue, we will utilize Mouse Clariom S Gene Expression Microarray (Affymetrix) and Gene 
Set Enrichment Analysis (GSEA; Broad Institute) to analyze expression of gene sets. 
Pathways involved in inflammation, tumor proliferation, apoptosis and drug resistance will be 
examined. This will allow us to identify common biological functions that are altered in the 
fasted state and in response to therapy. Within the tumor tissue, we will also confirm target 
inhibition of the HER2-directed drugs by extracting protein and performing western blotting 
to measure changes in phosphorylation of HER2 and downstream targets. Additionally, 
alterations in immune function will be assessed in the tumor and surrounding 
microenvironment. Immune infiltration in the tumor will be assessed by staining for T cell 





Several rodent studies have demonstrated that short-term fasting sensitizes cancer cells 
to chemotherapies in mouse models of lung, breast, and pancreatic cancer (34, 63, 88). 
However, this relationship has only been explored for HER2-positive breast cancer in vitro. 
We hypothesize that the combination of short-term fasting cycles with HER2-directed 
therapy administration will improve drug response and reduce tumor growth rates more than 
in mice that are fed continuously. Preliminary analyses of a subset of mice in the BT-474 
model after one round of therapy have indicated that intermittent fasting regimens adjuvant 
to trastuzumab reduce tumor growth more than in the mice fed without restriction. We 
predict that this decrease may occur through blockade of potential drug resistance pathways 
including reduced signaling through IGF1R and mTOR, similar to the mechanisms that 
enhanced the antiproliferative effect of the drugs in vitro in combination with MRIs. In vivo, 
we also predict that fasting will enhance the immune-mediated response within tumors and 
promote CD8+ tumor cytotoxicity. Work by Di Biase, et al. in a triple negative breast cancer 
model demonstrated that in mice on a fasting-mimicking diet timed around chemotherapy 
administration there were increased tumor infiltrating immune cells present (63). We predict 
that this will hold true in our model with 48-hour intermittent fasting because this regimen 
has been demonstrated to be safe for multiple mouse strains and more effective than 24-
hour fasting in reducing chemotherapy-induced toxicities and immunosuppression (95, 96). 
One important consideration with fasting mice for 48 hours is the potential adverse effects 
that could occur upon rapid re-feeding. Studies have demonstrated that mice lose ~20% of 
their body weight during a 48-hour fast and regain this weight to baseline within 
approximately 5 days, demonstrating that there is a significant compensatory feeding effect 
that occurs (34). One potential limitation of rapid refeeding is induction of the Crabtree 
effect, a short-term metabolic adaptation that cancer cells use to reversibly switch between 
oxidative and glycolytic metabolism in response to changes in their environment (97). In a 




restriction paradoxically increased cancer stemness and promoted the acquisition of a 
metastatic phenotype (98). While the models used in this current study are not prone to 
developing metastases, it is plausible that the metabolic flexibility of tumor cells could allow 
for increased growth in the refeeding period in the absence of anti-cancer therapy. However, 
since fasting combined with chemotherapy in models of breast cancer have demonstrated 
increased therapeutic efficacy in previous studies, we hypothesize that tumor growth rates 






CHAPTER 5: CONCLUSIONS 
 Study aims were designed to determine a method of translating the potent cancer-
preventative effects conferred by caloric restriction into the treatment setting for HER2-
positive breast cancer. It was hypothesized that modulating energy-responsive pathways 
implicated in drug resistance through either short-term fasting regimens or pharmacological 
MRIs could mimic the beneficial effects conferred by caloric restriction and increase efficacy 
of HER2-directed therapies. We determined that inhibition of IGF1R/IR and mTOR activation 
has the potential to enhance the antiproliferative effects of lapatinib; however, further 
investigation is necessary to determine if this effect can be strengthened with the addition of 
an autophagy inhibitor. Importantly, future experiments will also determine if combinations of 
MRIs can re-sensitize resistant HER2-positive breast cancer cell lines to lapatinib, which has 
translational potential. Ongoing work with dietary restriction will determine the impact of a 
48-hour intermittent fasting regimen on HER-2 directed therapeutic efficacy in vivo, which 
could have important population health implications if demonstrated to be tolerable and 
efficacious. Altogether, we conclude that modulation of metabolic pathways implicated in 
HER2-positive breast cancer drug resistance through intermittent fasting regimens and 
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